Bio News

Oscotec has licensed ADEL-Y01, an Alzheimer disease drug candidate targeting tau protein, to Sanofi in a deal worth a total of KRW 54.1 billion. The agreement is a revenue-sharing arrangement through co-development partner ADEL, with Oscotec set to receive 47% of the total amount. ADEL-Y01 is currently in a phase 1a trial in the United States, with completion of phase 1 targeted for 2026.

BIOBOOK TEAM
biobookmedia@biobook.co.krCG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug
Biogen Signs $411 Million Deal With Trimtech for Neurodegenerative Diseases
AstraZeneca’s new myasthenia gravis drug cligepa approved in the U.S. and EU
Helus meets primary endpoint in phase 3 trial of depression drug candidate, with 7.6-point improvement over placebo